The U.S. House Select Committee on China has opened investigations into five pharmaceutical companies regarding their clinical trials in China, questioning whether the drugmakers may have aided the country’s military biotechnology research.
Representatives from AbbVie, Bristol Myers Squibb, Eli Lilly & Co., Merck and Pfizer have until July 17 to answer letters sent to each by committee chairman Rep. John Moolenaar, R-Mich., requesting information detailing due diligence and other standards, including intellectual property and data protection, at clinical trial and manufacturing sites